Digest Réseau Comment ça marche
Réseau
/
Sociétés
Bo
Non vérifié

Boehringer Ingelheim Limited

Ce que nous écrivons

Annonces ÉconomiquesIndustrie pharmaceutiqueManagement/Organisation d'EntrepriseMédecine Santé Bien-êtrePublicité/Marketing/Médias/Communication

37 communiqués de presse

Voir tous les communiqués de presse
27/01/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
27/01/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
13/01/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
12/01/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
19/12/2025
Industrie pharmaceutique
Médecine Santé Bien-être
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
28/11/2025
Industrie pharmaceutique
Médecine Santé Bien-être
Boehringer Ingelheim announces appointment to Board of Managing Directors
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
04/11/2025
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Boehringer Ingelheim and CDR-Life Expand Collaboration Efforts with Global Licensing Agreement for CDR111, an Antibody-Based Trispecific M-gager® for Autoimmune Diseases
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
29/10/2025
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
22/10/2025
Industrie pharmaceutique
Médecine Santé Bien-être
JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
17/10/2025
Industrie pharmaceutique
Médecine Santé Bien-être
Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0